Imigran (Sumatriptan)

Sumatriptan acts as a selective agonist at 5‑HT1B and 5‑HT1D receptors located on cranial blood vessels and trigeminal nerve fibers. By stimulating these receptors, it causes vasoconstriction of dilated intracranial vessels and blocks the release of inflammatory neuropeptides, interrupting the migraine pain pathway.

The prescribed dose is determined by the treating clinician based on individual response and medical history. Typically, an adult receives a single spray delivering a defined microgram amount, with a possible second dose after a specified interval if the migraine persists. Patients should follow the prescriber’s instructions and not self‑adjust the dose.

Safety data for sumatriptan in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should be used only if the potential benefit justifies any potential risk to the fetus. Breastfeeding mothers should discuss use with their healthcare provider.

To place an order, submit an enquiry on the Imigran product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After verification of trade or institutional credentials, the sales team will respond with pricing, availability, shipping details (including any cold‑chain requirements) and required import documentation.

Imigran delivers sumatriptan via the nasal route, providing faster absorption than oral tablets and an alternative for patients who experience nausea or have difficulty swallowing. Compared with other triptans, its efficacy is similar, but the nasal spray may be preferred when rapid onset is desired or when oral administration is not feasible.

Imigran should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme heat. Do not refrigerate or freeze the nasal spray, and keep the cap tightly closed when not in use.

The patient should tilt the head slightly forward, insert the nozzle into one nostril, and press the actuator to deliver a single spray. The same procedure is repeated in the other nostril if a second dose is prescribed. Administration should be performed as soon as migraine symptoms begin, following the prescribing information.

Serious adverse events include chest pain or coronary vasospasm, myocardial infarction, severe hypertension, serotonin syndrome (especially when combined with serotonergic drugs), and severe allergic reactions such as anaphylaxis. If any of these symptoms occur, seek immediate medical attention.

Imigran is contraindicated in patients with known coronary artery disease, uncontrolled hypertension, a history of stroke, hemiplegic or basilar migraine, or those currently taking MAO inhibitors, ergot derivatives, or another triptan. Individuals with hypersensitivity to sumatriptan or any component of the formulation should also avoid its use.